Therapeutic benefit of melatonin in refractory central serous chorioretinopathy

Autores
Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; Luna, J. D.
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.
Fil: Gramajo, Ana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
Fil: Marquez, G. E.. Fundacion Ver; Argentina
Fil: Torres, Victor Eduardo Roque. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones y Estudio sobre Cultura y Sociedad; Argentina. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; Argentina
Fil: Juarez, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
Fil: Rosenstein, Ruth Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Luna, J. D.. Fundacion Ver; Argentina
Materia
Central Serous Chorioretinopathy
Melatonin
Optical Coherence Tomography (Oct)
Fluorescein Angiography
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/14003
Acceder
id CONICETDig_b78cb236976de6f7a5a6d524f1d956a6
oai_identifier_str oai:ri.conicet.gov.ar:11336/14003
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Therapeutic benefit of melatonin in refractory central serous chorioretinopathyGramajo, Ana LauraMarquez, G. E.Torres, Victor Eduardo RoqueJuarez, Cecilia PaolaRosenstein, Ruth EstelaLuna, J. D.Central Serous ChorioretinopathyMelatoninOptical Coherence Tomography (Oct)Fluorescein Angiographyhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.Fil: Gramajo, Ana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; ArgentinaFil: Marquez, G. E.. Fundacion Ver; ArgentinaFil: Torres, Victor Eduardo Roque. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones y Estudio sobre Cultura y Sociedad; Argentina. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; ArgentinaFil: Juarez, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; ArgentinaFil: Rosenstein, Ruth Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; ArgentinaFil: Luna, J. D.. Fundacion Ver; ArgentinaNature Publishing Group2015-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/14003Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; et al.; Therapeutic benefit of melatonin in refractory central serous chorioretinopathy; Nature Publishing Group; Eye; 29; 8; 8-2015; 1036-10450950-222X1476-5454enginfo:eu-repo/semantics/altIdentifier/url/http://www.nature.com/eye/journal/v29/n8/full/eye2015104a.htmlinfo:eu-repo/semantics/altIdentifier/doi/10.1038/eye.2015.104info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541344/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:27:25Zoai:ri.conicet.gov.ar:11336/14003instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:27:25.969CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
title Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
spellingShingle Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
Gramajo, Ana Laura
Central Serous Chorioretinopathy
Melatonin
Optical Coherence Tomography (Oct)
Fluorescein Angiography
title_short Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
title_full Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
title_fullStr Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
title_full_unstemmed Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
title_sort Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
dc.creator.none.fl_str_mv Gramajo, Ana Laura
Marquez, G. E.
Torres, Victor Eduardo Roque
Juarez, Cecilia Paola
Rosenstein, Ruth Estela
Luna, J. D.
author Gramajo, Ana Laura
author_facet Gramajo, Ana Laura
Marquez, G. E.
Torres, Victor Eduardo Roque
Juarez, Cecilia Paola
Rosenstein, Ruth Estela
Luna, J. D.
author_role author
author2 Marquez, G. E.
Torres, Victor Eduardo Roque
Juarez, Cecilia Paola
Rosenstein, Ruth Estela
Luna, J. D.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Central Serous Chorioretinopathy
Melatonin
Optical Coherence Tomography (Oct)
Fluorescein Angiography
topic Central Serous Chorioretinopathy
Melatonin
Optical Coherence Tomography (Oct)
Fluorescein Angiography
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.
Fil: Gramajo, Ana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
Fil: Marquez, G. E.. Fundacion Ver; Argentina
Fil: Torres, Victor Eduardo Roque. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones y Estudio sobre Cultura y Sociedad; Argentina. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; Argentina
Fil: Juarez, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
Fil: Rosenstein, Ruth Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
Fil: Luna, J. D.. Fundacion Ver; Argentina
description PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.
publishDate 2015
dc.date.none.fl_str_mv 2015-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/14003
Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; et al.; Therapeutic benefit of melatonin in refractory central serous chorioretinopathy; Nature Publishing Group; Eye; 29; 8; 8-2015; 1036-1045
0950-222X
1476-5454
url http://hdl.handle.net/11336/14003
identifier_str_mv Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; et al.; Therapeutic benefit of melatonin in refractory central serous chorioretinopathy; Nature Publishing Group; Eye; 29; 8; 8-2015; 1036-1045
0950-222X
1476-5454
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.nature.com/eye/journal/v29/n8/full/eye2015104a.html
info:eu-repo/semantics/altIdentifier/doi/10.1038/eye.2015.104
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541344/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781842417516544
score 12.982451

Publicaciones similares